; Whereas a person is at higher risk for tardive dyskinesia after taking DRBAs for 3 months or longer, but the longer the person is on these medications, the higher the risk of developing tardive dyskinesia; Whereas studies suggest that the overall risk of developing tardive dyskinesia after taking DRBAs is between 10 and 30 percent; Whereas it is estimated that over 600,000 people in the United States suffer from tardive dyskinesia; Whereas, according to the National Alliance for Mental Illness, 1 in every 4 patients receiving long-term treatment with an antipsychotic medication will experience tardive dyskinesia; Whereas years of difficult and challenging research have resulted in recent scientific breakthroughs, with 2 new treatments for tardive dyskinesia approved by the Food and Drug Administration of the Department of Health and Human Services; Whereas tardive dyskinesia is often unrecognized, and patients suffering from the illness are commonly misdiagnosed; Whereas regular screening for tardive dyskinesia in patients taking DRBA medications is recommended by the American Psychiatric Association; Whereas patients suffering from tardive dyskinesia often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and increasingly isolate themselves as the disease progresses; Whereas caregivers of patients with tardive dyskinesia face many challenges and are often responsible for the overall care of the tardive dyskinesia patient; and Whereas the House of Representatives can raise awareness of tardive dyskinesia in the public and medical community: Now, therefore, be it